Stock Markets
LianBio shares surge following termination of Bristol Myers agreement
© Reuters.
LianBio’s shares experienced a significant surge of 124% Tuesday morning following the termination of its mavacamten licensing agreement with Bristol Myers (NYSE:) Squibb. The termination of the agreement led to a $350 million windfall for LianBio and facilitated the transfer of exclusive development and commercialization rights for the FDA-approved heart medication, Camzyos, to Bristol Myers across several Asian territories.
This development comes on the heels of Bristol Myers’ acquisition of MyoKardia (NASDAQ:) for $13 billion in 2020. The termination also absolved LianBio from agreement obligations amounting to up to $127.5 million in future milestone payments.
The termination triggered an impending strategic review by LianBio, which is expected to conclude by the first half of 2024. Today’s developments resulted in a substantial rise in LianBio’s share price from $1.39 to $3.19.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
SUI DEADLINE TOMORROW: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sun Communities, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in S
Forex3 years agoForex Today: the dollar is gaining strength amid gloomy sentiment at the start of the Fed’s week
- Forex2 years ago
Unbiased review of Pocket Option broker
- Forex3 years ago
How is the Australian dollar doing today?
- Forex2 years ago
Dollar to pound sterling exchange rate today: Pound plummeted to its lowest since 1985
- Cryptocurrency3 years ago
What happened in the crypto market – current events today
- World2 years ago
Why are modern video games an art form?
- Commodities3 years ago
Copper continues to fall in price on expectations of lower demand in China
- Forex2 years ago
The dollar is down again against major world currencies
